Dr. Reddy's Launches Generic Semaglutide in Canada

Dr. Reddy's Laboratories discloses the launch of its generic Semaglutide Injection in Canada following Health Canada approval.
The company is the first to receive approval for generic Semaglutide in Canada, a first among G7 countries.
The product is indicated for type 2 diabetes and is available in 2 mg/pen and 4 mg/pen strengths.
CEO Erez Israeli highlighted the launch's significance for expanding access to affordable GLP-1 therapies.